Ascendis Pharma Q2 EPS $(2.06) Misses $(1.56) Estimate, Sales $38.76M Miss $92.74M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma reported Q2 losses of $(2.06) per share, missing the $(1.56) estimate. Sales were $38.76M, falling short of the $92.74M estimate. This reflects a 12.34% improvement in EPS from last year but a 24.97% decline in sales.
September 03, 2024 | 9:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ascendis Pharma's Q2 earnings report showed a significant miss on both EPS and sales estimates. The EPS of $(2.06) was below the expected $(1.56), and sales of $38.76M were far below the $92.74M estimate. Despite an improvement in EPS from last year, the substantial sales decline is concerning.
The significant miss on both EPS and sales estimates is likely to negatively impact Ascendis Pharma's stock price in the short term. The EPS was 32% below expectations, and sales were 58% below estimates, indicating potential operational challenges. Despite a year-over-year improvement in EPS, the large sales decline is a major concern for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100